According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
A number of other equities analysts also recently issued reports on the company. SunTrust Banks began coverage on Zoetis in a report on Tuesday, March 19th. They issued a hold rating and a $100.00 price objective for the company. Janney Montgomery Scott began coverage on PLx Pharma in a report on Friday, April 12th. They issued a buy rating for the company. Cantor Fitzgerald set a $135.00 price objective on Zimmer Biomet and gave the stock a buy rating in a report on Friday, April 26th. BidaskClub downgraded Zebra Technologies from a buy rating to a hold rating in a report on Tuesday, July 16th. Finally, ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $26.17.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.01. The business had revenue of $74.52 million during the quarter, compared to the consensus estimate of $70.10 million. Collegium Pharmaceutical had a negative return on equity of 30.87% and a negative net margin of 10.36%. On average, equities analysts predict that Collegium Pharmaceutical will post -0.46 EPS for the current year.
In related news, EVP Scott Dreyer sold 2,857 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $12.31, for a total transaction of $35,169.67. Following the sale, the executive vice president now directly owns 40,596 shares of the company’s stock, valued at $499,736.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $11.26, for a total value of $281,500.00. Following the sale, the director now directly owns 132,069 shares in the company, valued at $1,487,096.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,144 shares of company stock worth $1,075,506. Insiders own 8.08% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in COLL. Millennium Management LLC boosted its position in shares of Collegium Pharmaceutical by 863.4% during the fourth quarter. Millennium Management LLC now owns 1,305,001 shares of the specialty pharmaceutical company’s stock valued at $22,407,000 after buying an additional 1,169,537 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in shares of Collegium Pharmaceutical by 27.8% during the first quarter. Rice Hall James & Associates LLC now owns 1,191,141 shares of the specialty pharmaceutical company’s stock valued at $18,034,000 after buying an additional 259,015 shares during the last quarter. Cortina Asset Management LLC boosted its position in shares of Collegium Pharmaceutical by 81.0% during the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after buying an additional 228,035 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Collegium Pharmaceutical by 8.7% during the fourth quarter. Macquarie Group Ltd. now owns 2,759,007 shares of the specialty pharmaceutical company’s stock valued at $47,372,000 after buying an additional 221,779 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of Collegium Pharmaceutical by 8.7% during the fourth quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock valued at $44,980,000 after buying an additional 210,145 shares during the last quarter. 94.83% of the stock is currently owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Article: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.